Alivus Life Sciences Limited (NSE:ALIVUS)
India · Delayed Price · Currency is INR | Market Cap | 129.55B -5.3% |
| Revenue (ttm) | 25.52B +6.9% |
| Net Income | 5.64B +16.2% |
| EPS | 45.90 +16.1% |
| Shares Out | 122.74M |
| PE Ratio | 23.00 |
| Forward PE | 20.57 |
| Dividend | 5.00 (0.47%) |
| Ex-Dividend Date | Sep 1, 2025 |
| Volume | 73,311 |
| Open | 1,060.70 |
| Previous Close | 1,055.50 |
| Day's Range | 1,035.00 - 1,089.90 |
| 52-Week Range | 819.00 - 1,148.40 |
| Beta | 0.06 |
| Analysts | Strong Buy |
| Price Target | 1,228.75 (+17.25%) |
| Earnings Date | May 14, 2026 |
About Alivus Life Sciences
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health,... [Read more]
Financial Performance
In fiscal year 2026, Alivus Life Sciences's revenue was 25.52 billion, an increase of 6.91% compared to the previous year's 23.87 billion. Earnings were 5.64 billion, an increase of 16.24%.
Financial StatementsNews
Alivus Life Sciences Transcript: Q4 25/26
Revenue and profitability grew strongly in FY 2026, driven by non-GPL and CDMO segments, margin expansion, and disciplined cost management. CapEx is fully funded internally, with new capacity and backward integration expected to support future growth.
Alivus Life Sciences Quarterly report: Q4 2026
Alivus Life Sciences has published its Q4 2026 quarterly earnings report on May 14, 2026.
Alivus Life Sciences Slides: Q4 2026
Alivus Life Sciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 14, 2026.
Alivus Life Sciences Transcript: Q3 25/26
Q3FY26 saw record revenue and margins, led by a strong CDMO rebound and robust API generics growth. High single-digit revenue growth and 30%-32% margins are guided for FY26-FY27, with double-digit growth expected from FY28 as new capacity ramps up.
Alivus Life Sciences Quarterly report: Q3 2026
Alivus Life Sciences has published its Q3 2026 quarterly earnings report on January 22, 2026.
Alivus Life Sciences Slides: Q3 2026
Alivus Life Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 22, 2026.
Alivus Life Sciences Transcript: Q2 25/26
Q2 FY 2026 saw 16% YoY revenue growth to INR 588 crore, with strong non-GPL and new product launches driving performance. Margins improved, and guidance for high single-digit growth is reaffirmed, with H2 expected to benefit from a rebound in GPL and CDMO segments.
Alivus Life Sciences Quarterly report: Q2 2026
Alivus Life Sciences has published its Q2 2026 quarterly earnings report on November 6, 2025.
Alivus Life Sciences Slides: Q2 2026
Alivus Life Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.
Alivus Life Sciences Transcript: Q1 25/26
Q1 FY26 saw 2.2% YoY revenue growth to INR 602 crore, with strong margins and robust cash flow. Non-GPL business led growth, while GPL is expected to recover in H2. CDMO ramp-up and new launches support a positive outlook, with margins guided at 28–30%.
Alivus Life Sciences Quarterly report: Q1 2026
Alivus Life Sciences has published its Q1 2026 quarterly earnings report on August 1, 2025.
Alivus Life Sciences Slides: Q1 2026
Alivus Life Sciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 1, 2025.